Major impact from early use of abiraterone + ADT in metastatic disease

The abstracts of the LATITUDE trial and the comparable arm of the STAMPEDE trial, in which patients with newly diagnosed, metastatic prostate cancer were randomized to either ADT or ADT + abiraterone acetate + prednisone were both released this morning. Both trials have shown major benefits to the early addition of abiraterone acetate to standard care. We shall be providing more details in separate reports to come later today.

15-year metastasis-free survival in men on active surveillance in The Netherlands

According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. … READ MORE …

Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …

Prostate cancer statistics in America, 2017

As it does every year, the American Cancer Society (ACS) has just published it’s annual update cancer statistics update: Cancer Facts & Figures 2017. Those who are interested are of course welcome to peruse this detailed document for themselves. What follows is a quick summary of the prostate cancer-related data in the ACS update. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

Outcomes, survival, and HRQOL in trials of new drugs (and what they mean in practice)

A new paper in the journal Quality of Life Research has raised the question of whether it is possible to use available quality of life data from Phase III trials of new drugs in the treatment of advanced prostate cancer to make rational decisions about the use of those drugs in clinical practice. … READ MORE …

Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …